Stoke Therapeutics Income Statement (2018-2026) | STOK

Income Statement Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
3.00M3.23M2.90M3.27M5.15M2.48M3.31M2.80M4.22M4.83M4.89M22.61M158.57M13.82M10.63M1.40M6.23M9.32M
Operating items
Research & Development (Quarter)
14.36M15.80M18.31M18.36M20.11M21.06M19.63M20.55M20.27M21.78M22.37M21.14M22.20M23.42M32.68M25.86M37.70M41.70M39.67M49.50M
Selling, General & Administrative (Quarter)
8.32M8.72M9.49M10.11M9.94M9.38M10.21M10.23M10.27M10.61M10.22M13.04M12.69M12.84M14.65M15.26M16.03M21.15M19.97M25.25M
Other Operating Expenses (Quarter)
-133.63M-38.47M-44.93M152.37M
Operating Expenses (Quarter)
22.68M24.53M27.80M28.47M30.05M30.44M29.84M30.78M30.54M-101.24M32.59M34.17M-3.57M36.27M47.33M-3.82M53.72M215.21M59.65M74.75M
Operating Income (Quarter)
-22.68M-24.53M-24.80M-25.24M-27.15M-27.18M-24.69M-33.26M-27.23M-29.59M-28.37M-29.34M-30.00M-13.65M111.24M-27.30M-43.09M-61.44M-53.42M-65.43M
EBIT (Quarter)
-22.68M-24.53M-24.80M-25.24M-27.15M-27.18M-24.69M-33.26M-27.23M-29.59M-28.37M-29.34M-30.00M-13.65M111.24M-27.30M-43.09M-61.44M-53.42M-65.43M
Non-operating items
Interest & Investment Income (Quarter)
0.02M-0.15M-0.52M-0.59M-0.43M0.53M0.58M0.22M0.23M0.12M0.02M-0.01M0.18M-0.32M2.89M0.20M0.35M0.10M-0.66M3.52M
Other Non Operating Income (Quarter)
0.04M0.04M0.04M0.04M0.04M0.04M0.04M0.04M0.04M0.04M-0.43M-0.05M0.03M0.20M0.03M0.03M0.00M-0.11M0.02M0.31M
Non Operating Income (Quarter)
0.09M-0.03M0.10M0.54M1.04M1.35M2.15M2.61M2.65M2.63M2.00M3.65M3.57M3.17M2.92M3.79M3.46M3.56M3.42M3.81M
Net income details
EBT (Quarter)
-25.27M-90.70M-26.00M-32.19M-29.28M-124.55M-24.71M-37.09M-27.17M-162.77M-26.37M-25.70M-26.43M-14.74M114.16M-23.48M-39.62M-62.44M-50.00M-61.62M
Tax Provisions (Quarter)
1.28M-1.28M
Profit After Tax (Quarter)
-22.60M-24.45M-24.65M-24.65M-26.11M-25.66M-22.55M-30.65M-24.31M-26.84M-26.37M-25.70M-26.43M-10.48M112.93M-23.48M-38.00M-58.53M-50.00M-62.05M
Income from Continuing Operations (Quarter)
-25.27M-90.70M-26.00M-32.19M-29.28M-124.55M-24.71M-37.09M-27.17M-162.77M-26.37M-25.70M-26.43M-14.74M112.88M-23.48M-38.35M-62.44M-50.00M-61.62M
Consolidated Net Income (Quarter)
-25.27M-90.70M-26.00M-32.19M-29.28M-124.55M-24.71M-37.09M-27.17M-162.77M-26.37M-25.70M-26.43M-14.74M112.88M-23.48M-38.35M-62.44M-50.00M-61.62M
Income towards Parent Company (Quarter)
-25.27M-90.70M-26.00M-32.19M-29.28M-124.55M-24.71M-37.09M-27.17M-162.77M-26.37M-25.70M-26.43M-14.74M112.88M-23.48M-38.35M-62.44M-50.00M-61.62M
Net Income towards Common Stockholders (Quarter)
-25.27M-90.70M-26.00M-32.19M-29.28M-124.55M-24.71M-37.09M-27.17M-162.77M-26.37M-25.70M-26.43M-14.74M112.88M-23.48M-38.35M-62.44M-50.00M-61.62M
Additional items
EPS (Basic) (Quarter)
-0.69-2.47-0.69-0.82-0.74-3.20-0.58-0.84-0.61-3.70-0.57-0.46-0.47-0.271.95-0.40-0.65-1.05-0.79-0.93
EPS (Diluted) (Quarter)
-0.69-2.47-0.69-0.82-0.75-3.20-0.58-0.84-0.61-3.70-0.57-0.46-0.47-0.271.90-0.40-0.65-1.05-0.79-0.93
Shares Outstanding (Quarter)
36.76M36.74M37.45M39.26M39.42M38.90M42.54M44.19M44.27M43.99M46.25M55.77M56.34M54.01M57.86M58.35M58.61M59.22M63.06M66.02M
Shares Outstanding (Diluted) (Quarter)
36.71M36.74M37.45M39.26M39.26M38.90M42.54M44.19M44.27M43.99M46.25M55.77M56.34M54.01M59.40M58.35M58.61M59.22M63.06M66.02M
Shares Outstanding (Entity) (Quarter)
36.78M36.90M39.04M39.38M39.43M39.44M44.18M44.20M44.29M45.92M46.50M52.31M52.94M54.03M54.60M54.72M55.12M58.92M62.24M62.40M
EBITDA (Quarter)
-22.68M-24.53M-24.80M-25.24M-27.15M-27.18M-24.69M-33.26M-27.23M-29.59M-28.37M-29.34M-30.00M-13.65M111.24M-27.30M-43.09M-61.44M-53.42M
Interest Expenses (Quarter)
2.61M66.03M0.68M6.36M1.70M97.90M0.60M4.05M0.17M133.31M0.02M0.01M0.77M0.00M5.83M0.00M1.09M0.02M
Tax Rate (Quarter)
1.12%3.23%